We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Pioneering Infectious Disease Testing Platform Now Available in Europe

By LabMedica International staff writers
Posted on 23 Dec 2014
A first-of-its-kind diagnostics technology platform to enable healthcare professionals to more quickly diagnose serious infections is now available in Europe and other CE marking recognized countries worldwide. More...


The new platform called IRIDICA was developed by Abbott (Abbott Park, IL, USA) and it can identify over 1,000 infection-causing pathogens in less than 6 hours—much quicker than the current standard-of-care (culture-based testing), which can take days, in some cases weeks. Every minute can count with serious infections and this technology was developed to give doctors information needed to act more quickly and effectively in making life-saving decisions. IRIDICA, which currently offers 5 testing panels, has the potential to change how pathogens are detected and identified.

“Doctors need better tools to diagnose people with serious infections,” said Prof. François Simon, MD, PhD, chief of Microbiology at Hôpital Saint-Louis (Paris, France). “For those with sepsis, the survival rate decreases each hour treatment is delayed.”

IRIDICA employs Polymerase Chain Reaction/Electrospray Ionization Mass Spectrometry (PCR/ESI-MS) to rapidly identify infection-causing pathogens directly from a patient’s sample, without culture. According to Abbott’s “RApid Diagnosis of Infections in the CriticAlly IlL” (RADICAL) study results, the technology was able to detect pathogens when the current standard-of-care did not. In the study, after retrospectively comparing the results of Abbott’s technology versus culture, an independent panel of physicians concluded it would have prescribed a different course of treatment in nearly 60% of cases evaluated. Additional analysis suggested it could help lower associated health care costs by 30% and reduce hospital stays for people with serious infections by up to 8 days (for a hospital that sees approximately 500 patients with blood-related infections each year. Costs were derived from intensive care and non-intensive care lengths of stay).

"Currently, when a person enters a hospital with a suspected infection, it may take several days before the source can be accurately identified," said David J. Ecker, PhD, divisional vice president, R&D, Ibis Biosciences, Abbott, "IRIDICA can offer a better and faster way."

IRIDICA also represents a step forward in combating overuse of antibiotics. "Slower diagnostic methods, like cultures, have led to the overuse of broad-spectrum antibiotics and antimicrobials and an emergence of new resistant superbugs," said Jean-Louis Vincent, MD, PhD, professor of Intensive Care, Université Libre de Bruxelles (Belgium). "By identifying pathogens faster with IRIDICA, a doctor can quickly prescribe the most effective therapy, potentially limiting the indiscriminate use of broad-spectrum antibiotics."

Related Links:

Abbott



New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining System
RAL DIFF-QUIK
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.